Prosecution Insights
Last updated: November 04, 2026
Application No. 18/782,470

TRANSDERMAL CARRIER

Non-Final OA §103§DOUBLEPATENT
Filed
Jul 24, 2024
Priority
Dec 23, 2014 — CIP of PCTUS2014072239 +23 more
Examiner
SONG, JIANFENG
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dyve Biosciences Inc.
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
4m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
492 granted / 872 resolved
-3.6% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
67 currently pending
Career history
950
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
48.5%
+8.5% vs TC avg
§102
10.3%
-29.7% vs TC avg
§112
17.9%
-22.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 872 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicants elect sodium bicarbonate as specific active agent, claims 21 and 27-35 read on the elected species and are under examination. Claims 22-26 do not read on the excocted spices and are withdrawn from consideration. Claims 21-35 are pending, claims 21 and 27-35 are under examination. Priority Acknowledge is made that this application is a continuation of US Application No. 17934056, filed on 09/21/2022; which is a continuation of US Application No. 17361158, filed on 06/28/2021; which is a continuation of US Application No. 17030325, filed 09/23/2020; which a is a continuation of US Application No. 16119178, filed on 08/31/2018; which is a continuation of US Application No. 15/994,927, filed 31 May 2018; which application is a continuation of US Application No. 14/757,703 filed 23 December 2015; which application is a continuation-in-part of PCT application PCT/US2014/072239, having an international filing date of 23 December 2014; and claims priority from U.S. Provisional Application No. 62/176,416, filed 17 February 2015; U.S. Provisional Application No. 62/198,605, filed 29 July 2015; U.S. Provisional Application No. 62/187,756, filed 1 July 2015; U.S. Provisional Application No. 62/176,418, filed 17 February 2015; U.S. Provisional Application No. 62/191,952, filed 13 July 2015; U.S. Provisional Application No. 62/178,232, filed 6 April 2015; U.S. Provisional Application No. 62/198,599, filed 29 July 2015; U.S. Provisional Application No. 62/177,814, filed 24 March 2015; U.S. Provisional Application No. 62/261,167, filed 30 November 2015; U.S. Provisional Application No. 62/176,438, filed 17 February 2015; U.S. Provisional Application No. 62/176,417, filed 17 February 2015; U.S. Provisional Application No. 62/176,414, filed 17 February 2015; U.S. Provisional Application No. 62/176,415, filed 17 February 2015; U.S. Provisional Application No. 62/176,419, filed 17 February 2015; U.S. Provisional Application No. 62/178,192, filed 2 April 2015; U.S. Provisional Application No. 62/238,012, filed 6 October 2015; and U.S. Provisional Application No. 62/178,193, filed 2 April 2015. Information Disclosure Statement The information disclosure statement (IDS) submitted on 10/23/2024 is being considered by the examiner. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 21, 27-29 are rejected under 35 U.S.C. 103 as being unpatentable over Carter et al. (US20060013866). Determination of the scope and content of the prior art (MPEP 2141.01) Carter et al. teaches a composition effective for delivering specific drug through the skin and into the bloodstream, and more particularly to a composition effective for delivering a specific drug through the outer layers of skin and into the surrounding skin tissue by transdermal delivery (page 1, [0007, 0009]). The excipients in the composition includes penetration enhancer, isopropanol, propylene glycol and menthol (page 4, [0034-0035]). The active drug molecules that are candidates for transdermal drug delivery include sodium bicarbonate (page 4-5, [0036]). Typically the concentrations of the active drug molecule range from 0.05% to 20% of the delivery vehicle formulation (page 5, [0037]). Ascertainment of the difference between the prior art and the claims (MPEP 2141.02) The difference between the instant application and Carter et al. is that Carter et al. is not specific enough for anticipation. Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143) It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to produce the instant invention. Regarding Claims 21, 27-29, Carter et al. teaches a transdermal formulation comprising sodium bicarbonate at 0.05% to 20%, isopropanol (solvent) and penetration enhancer (penetrant portion). In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Claims 30-35 are rejected under 35 U.S.C. 103 as being unpatentable over Carter et al. (US20060013866), as applied for the above 103 rejection for claims 21 and 27-29, in view of Sand et al. (US20090053290). Determination of the scope and content of the prior art (MPEP 2141.01) Carter et al. teaching has already been discussed in the above 103 rejection and is incorporated herein by reference. Sand et al. teaches transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment; the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents including anti-fungal agents, anesthetics (abstract). One embodiment of a transdermal drug delivery composition includes two or more transdermal penetrants working synergistically but by disparate biochemical pathways. As used herein, the term "penetrant" refers to agents or compounds capable of penetrating the outer layers of the skin and/or agents or compounds capable of enhancing the permeability of the skin. These inventive transdermal delivery compositions transport target drugs or agents through the epidermis rapidly into the dermis. According to one embodiment, the delivery composition includes a first penetrant and a second penetrant, where each of the first and second penetrants is any suitable agent capable of penetrating the stratum corneum. The first and second penetrants work synergistically to enhance permeability of the outer skin layers and may follow disparate biochemical pathways (page 4, [0044]). In one embodiment, the first penetrant benzyl alcohol is at an amount of about 1% to about 20% of transdermal composition, and the second penetrant lecithin organogel (soybean lecithin / isopropyl palmitate) is at amount of about 0.5% to about 20% of the composition (page 5, [0051-0053]; claims 1-8). Both Pluronic 127 (about 0.5-15%), poloxamer (231, 182,184) and sodium lauryl sulfate are mentioned as penetrant (page 4, [0049]; page 5, [0057). In one embodiment, the composition has a pH ranging from acid to physiological, e.g. from about 3.0 to about 7.4 (page 6, [0069]). The topical composition may include pharmaceutically acceptable carrier such as ethanol, nonionic surfactant, for example, ethylene oxide / propylene oxide block copolymer Pluronic F127 (page 8, [0089-0091]). The carrier may include water, propylene glycol, etc. (page 8, [0092]). In an alternative embodiment, the topical composition may include an anhydrous delivery system and may include a volatile co-solvent such as propylene glycol, 2,2'-ethoxyethoxyethanol, menthol, isopropyl alcohol (page 26, [0319-0320]; page 29, [0350]). Propylene glycol is also a penetration enhancer and used at an amount of about 10 to about 20% (page 14, [0166]). The inventive topical compositions described herein may be made by any suitable method, including standard methods used to make cosmetic preparations and pharmaceutical compositions intended for application on the skin. Non-limiting examples of suitable procedures include mixing techniques (both manual and mechanical mixing), homogenization mixing and sweep mixing. The mixing techniques can be chosen based on variables such as the viscosity of the components to be mixed and the volume of those components, as well as the relative proportion of lipid-soluble and water-soluble ingredients. The individual active ingredients may be added sequentially, and benzyl alcohol and/or other transepidermal delivery agents are added to the desired final concentration (page 23, [0274]). The composition further comprises antioxidant (page 2, [0020]), and the intended drug is present in the micelle of the lecithin organogel (page 5, [0059]). Some active agent such as tetracaine is included from about 3% to about 5% (page 26, [0318]). The combination of benzocaine, lidocaine and tetracaine is also recited (page 26, [0316]). The cross-linking agent may be present in the composition in any quantity sufficient to accelerate restoration of the integrity and fullness of the skin. In one embodiment, the cross-linking agent is a bioflavonoid selected from quercetin, quercitrin, kaempferol, kaempferol 3-rutinoside, 3'-methoxy kaempferol 3-rutinoside, 5,8,4'-trihydroxyl-6,7-dimethoxyflavone, catechin, epicachetin, epicachetin gallate, epigallocachetin gallate, hesperidin, naringin, rutin, vixetin, proanthocyanidin, apigenin, myricetin, tricetin, quercetin, naringin, kaernpferol, luteolin, biflavonyl, silybin, silydianin, and silychristin, and derivatives and glycosides of these compounds (page 16, [0190]). In another alternative embodiment, the cross-linking agent may be a flavonoid that is a component of silymarin (page 19, [0232]). The amino acid may be present in the composition to accelerate restoration of the integrity and fullness of the skin and the amino acid includes leucine and valine (page 15-16, [0183, 0189]). Ascertainment of the difference between the prior art and the claims (MPEP 2141.02) The difference between the instant application and Carter et al. is that Carter et al. do not expressly teach lecithin, poloxamer, benzyl alcohol, ethanol and amino acid. This deficiency in Carter et al. is cured by the teachings of Sand et al. Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143) It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of Carter et, as suggested by Sand et al., and produce the instant invention. One of ordinary skill in the art would have been motivated to include lecithin organogel (lecithin / isopropyl palmitate), benzyl alcohol, pluronic (poloxamer) and sodium lauryl sulfate to the transdermal formulation because they are suitable penetrant as suggested by Sand et al. MPEP 2144.07, The selection of a known material based on its suitability for its intended use supported a prima facie obviousness determination in Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945). Under guidance from Carter et al. teaching penetration enhancer; it is obvious for one of ordinary skill in the art to include lecithin organogel (lecithin / isopropyl palmitate), benzyl alcohol, pluronic (poloxamer) and sodium lauryl sulfate, and produce instant claimed invention with reasonable expectation of success. One of ordinary skill in the art would have been motivated to include ethanol and amino acid such as leucine and valine to the transdermal formulation because they are suitable solvent and ingredient to accelerate restoration of the integrity and fullness of the skin as suggested by Sand et al. MPEP 2144.07, The selection of a known material based on its suitability for its intended use supported a prima facie obviousness determination in Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945). It is obvious for one of ordinary skill in the art to ethanol and amino acid such as leucine and valine to the transdermal formulation and produce instant claimed invention with reasonable expectation of success. Regarding claims 30 and 32, prior art teaches 0.05 to 20% of sodium bicarbonate; lecithin organogel (soybean lecithin / isopropyl palmitate) is at amount of about 0.5% to about 20%, about 1 to 20% of benzyl alcohol, poloxamer (pluronic) as penetrant at an amount of about 1% to about 20%. Although the ratio of lecithin / ispropyl palmitate is not specified, at least 1:1 is obvious, then lecithin is at 0.25% to about 10%, overlapped with claimed amount of 5%-15%. Regarding claim 31, prior arts teach menthol and are silent about amount of menthol, and the amount of menthol is adjustable and one artisan in the art would have been motivated to optimize the amount of menthol through routing experimentation to have about 0.1% to 5%, especially in the absence of showing criticality of claimed range. MPEP 2144.05. Regarding claim 33, prior art teaches ethanol. Regarding claims 34, prior art teaches amino acid, which is regarded as nutrient. Since amino acid is readily metabolized, the limitation of readily metabolized nutrient is met. Regarding claims 35, prior art teaches amino acid such as leucine and valine, which are branched chain amino acids according to applicant’s specification. In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 11491225 in view of Sand et al. (US20090053290). The reference patent teaches applicant’s claimed transdermal composition comprising lecithin at 5%-15% w/w of the formulation, sodium bicarbonate at 20%-40% w/w of the formulation, a poloxamer 407 at 1%-15% w/w of the formulation, benzyl alcohol at 0.5%-20%, an isopropyl palmitate, ethanol and amino acid;except menthol, in view of Sand et al. teaching menthol as suitable ingredient in transdermal patch formulation, it is obvious to include menthol and produce applicant’s claimed invention with reasonable expectation of success. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 11052152 in view of Sand et al. (US20090053290). The reference patent teaches applicant’s claimed transdermal composition comprising lecithin at 5%-15% w/w of the formulation, sodium bicarbonate at 20%-40% w/w of the formulation, a poloxamer 407 at 1%-15% w/w of the formulation, benzyl alcohol at 0.5%-20%, an isopropyl palmitate, ethanol and amino acid;except menthol, in view of Sand et al. teaching menthol as suitable ingredient in transdermal patch formulation, it is obvious to include menthol and produce applicant’s claimed invention with reasonable expectation of success. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 12070503. The reference patent teaches applicant’s claimed transdermal composition comprising lecithin at 5%-15% w/w of the formulation, sodium bicarbonate at 20%-40% w/w of the formulation, a poloxamer 407 at 1%-15% w/w of the formulation, benzyl alcohol at 0.5%-20%, an isopropyl palmitate, ethanol and amino acid and menthol; it is obvious to include menthol and produce applicant’s claimed invention with reasonable expectation of success. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 10933088 in view of Sand et al. (US20090053290). The reference patent teaches applicant’s claimed transdermal composition comprising sodium bicarbonate (claim 1) at 1-35% w/w of the formulation (claim 14) and penetrant 5-55% (claim 15), but silent about lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol and amino acid and menthol, in view of Sand et al. teaching lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol as suitable ingredient in transdermal patch formulation, it is obvious to include lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol and produce applicant’s claimed invention with reasonable expectation of success. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11389472 in view of Sand et al. (US20090053290). The reference patent teaches applicant’s claimed transdermal composition comprising sodium bicarbonate (claim 1) at 30-35% w/w of the formulation (claim 7 and penetrant (claim 16), but silent about lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol and amino acid and menthol, in view of Sand et al. teaching lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol as suitable ingredient in transdermal patch formulation, it is obvious to include lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol and produce applicant’s claimed invention with reasonable expectation of success. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11730756 in view of Sand et al. (US20090053290). The reference patent teaches applicant’s claimed transdermal composition comprising sodium bicarbonate at 30-35% w/w of the formulation (claim 7) and penetrant 5-55% (claim 11), but silent about lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol and amino acid and menthol, in view of Sand et al. teaching lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol as suitable ingredient in transdermal patch formulation, it is obvious to include lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol and produce applicant’s claimed invention with reasonable expectation of success. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11744853 in view of Sand et al. (US20090053290). The reference patent teaches applicant’s claimed transdermal composition comprising sodium bicarbonate at 10-45% w/w of the formulation (claim 7) and penetrant 5-55% (claim 14), but silent about lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol and amino acid and menthol, in view of Sand et al. teaching lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol as suitable ingredient in transdermal patch formulation, it is obvious to include lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol and produce applicant’s claimed invention with reasonable expectation of success. Claims 21 and 27-35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 12310983 in view of Sand et al. (US20090053290). The reference patent teaches applicant’s claimed transdermal composition comprising sodium bicarbonate at 5-35% w/w of the formulation (claim 11) and penetrant (claim 3), but silent about lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol and amino acid and menthol, in view of Sand et al. teaching lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol as suitable ingredient in transdermal patch formulation, it is obvious to include lecithin, a poloxamer 407, benzyl alcohol, an isopropyl palmitate, ethanol, amino acid and menthol and produce applicant’s claimed invention with reasonable expectation of success. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JIANFENG SONG, Ph.D. whose telephone number is (571)270-1978. The examiner can normally be reached on M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached on (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JIANFENG SONG/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Jul 24, 2024
Application Filed
Oct 16, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773378
METHOD FOR THE COSMETIC TREATMENT OF KERATIN FIBRES COMPRISING A STAGE OF APPLICATION OF A RARE EARTH METAL COMPOSITION AND A STAGE OF APPLICATION OF A COMPOSITION COMPRISING SURFACTANTS
4y 4m to grant Granted Oct 27, 2026
Patent 12773382
BIOFILM REMOVER AND BIOFILM REMOVAL METHOD
2y 10m to grant Granted Oct 27, 2026
Patent 12766106
MICROPARTICLES CONTAINING MOXIDECTIN, AND PREPARATION METHOD THEREFOR
2y 8m to grant Granted Oct 20, 2026
Patent 12758519
FELINE FOOD COMPOSITION
5y 2m to grant Granted Oct 13, 2026
Patent 12734134
HERBAL BIOACTIVES BASED IMMUNOSTIMULANT FORMULATION FOR POULTRY BIRDS & CATTLE AND PREPARATION THEREOF
3y 1m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
89%
With Interview (+32.8%)
2y 8m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 872 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month